UChicago Medicine Working to Offer Breakthrough CAR T-Cell Gene Therapy Approved Today by FDA – Newswise (press release)
|
UChicago Medicine Working to Offer Breakthrough CAR T-Cell Gene Therapy Approved Today by FDA
Newswise (press release) “CAR T-cell therapy has revolutionized the treatment of acute lymphoblastic leukemia,” according to cancer specialist John Cunningham, MD, chair of pediatrics at the University of Chicago and physician-in-chief at Comer Children’s Hospital. “I came to … |
The Scientist |
First CAR T-Cell Therapy Approved in US
The Scientist ALLINONEMOVIE, PIXABAYThe US Food and Drug Administration (FDA) announced today (August 30) that it has approved the first therapy involving chimeric antigen receptor (CAR) T cells for clinical use. Each dose of Novartis’s drug, Kymriah, will consist … |
|
UChicago Medicine working to offer breakthrough CAR T-cell gene therapy approved by FDA
EurekAlert (press release) “CAR T-cell therapy has revolutionized the treatment of acute lymphoblastic leukemia,” according to cancer specialist John Cunningham, MD, chair of pediatrics at the University of Chicago and physician-in-chief at Comer Children’s Hospital. “I came to … |
|
US clears first ‘living drug’ for tough childhood leukemia
ModernHealthcare.com The CAR–T cell treatment developed by Novartis Pharmaceuticals and the University of Pennsylvania is the first type of gene therapy to hit the U.S. market — and one in a powerful but expensive wave of custom-made “living drugs” being tested against … |
Medical Xpress |
Blunting CRISPR’s ‘scissors’ gives new insight into autoimmune …
Science Daily A research team has used a modified version of the gene-editing technique CRISPR to find enhancers — not by editing them but by prompting them into action. CRISPRa Method Identifies Gene Enhancers Affecting T Cell …GenomeWeb |
|
US clears first ‘living drug’ for tough childhood leukemia
Orlando Sentinel The CAR–T cell treatment developed by Novartis Pharmaceuticals and the University of Pennsylvania is the first type of gene therapy to hit the U.S. market — and one in a powerful but expensive wave of custom-made “living drugs” being tested against … |